A number of malaria proteins have been proposed as candidates for inclusion in subunit vaccines against asexual blood stages of Plasmodium falciparum (30) . One of the most promising antigens in this respect is the 19-kDa C-terminal region of merozoite surface protein 1 (MSP1). P. falciparum MSP1 is expressed on the surfaces of merozoites and is proteolytically processed in two steps to generate first a complex of polypeptides including a 42-kDa fragment (MSP1 42 ) that is subsequently cleaved to a 19-kDa fragment (MSP1 19 ) and a 33-kDa fragment (MSP1 33 ). The complex containing MSP1 33 is shed (7) , and MSP1 19 is the only part of MSP1 that remains on the merozoite surface during parasite invasion of red blood cells (RBC) (6) . The MSP1 19 region consists of two epidermal growth factor-like domains (8) . A limited number of allelic variants of P. falciparum MSP1 19 occur, with minor amino acid differences between them, making MSP1 19 one of the most conserved regions of P. falciparum MSP1 (48, 57) . Importantly, MSP1 is expressed in other Plasmodium species and the processing that generates MSP1 19 appears to be similar (5, 17, 29, 43) , enabling the use of various malaria parasites and animal models for the study of MSP1 19 -induced protection.
Both antibodies and effector T cells appear to play important roles in the protection of mice against Plasmodium yoelii (4, 23, 28) . However, the protective immunity induced by vaccination with recombinant P. yoelii MSP1 19 is mediated largely by antibodies (14, 28, 36) . Passive transfer of MSP1 19 -specific antiserum or monoclonal antibodies (MAb) into naive mice suppressed an otherwise lethal P. yoelii infection (14, 39, 55) , whereas vaccination with MSP1 19 failed to protect mice deficient in immunoglobulin -chains (28) . In contrast, immunization with defined MSP1 19 -derived T-cell epitopes does not induce protective immunity and transfer of T-cell lines from MSP1 19 -immunized mice does not confer protection to naive recipients (58) . Nevertheless, a functional CD4 ϩ T-cell response is a prerequisite for the generation of potent humoral responses by vaccination with protein antigens.
Several parameters can be modified in order to enhance the protection induced by vaccination with pathogen-derived proteins or protein subunits. Optimized immunization protocols as well as the use of different adjuvants have been shown to have an impact on protective immunity elicited by P. yoelii MSP1 19 (15, 28, 38) . Another strategy would be to link additional T-cell epitopes to MSP1 19 to overcome limited recognition of T-helper-cell epitopes. This procedure may be suitable for improving the H-2-dependent protection against lethal P. yoelii infection induced by glutathione S-transferase (GST)-MSP1 19 fusion proteins (59) . In inbred mouse strains, GST-MSP1 19 elicited a higher degree of protection in C57BL/10 (H-2 b ) mice than in B10.A(4R) mice (H-2 k/b ), and B10.BR mice (H-2 k ) were poorly protected (59) . Partial protection against P. falciparum and Plasmodium vivax has been obtained in monkeys vaccinated with the respective MSP1 19 proteins linked to T-cell epitopes from tetanus toxoid (TT) (34, 61) . However, the impact of the T-cell epitopes on protective immune responses is uncertain, as comparisons with MSP1 19 alone were not made. Moreover, expression of P. falciparum MSP1 19 in the yeast Saccharomyces cerevisiae resulted, to a large extent, in proteolytic cleavage of the linked T-cell epitopes (34) .
To evaluate a strategy to improve the protection induced by P. yoelii MSP1 19 , GST fusion proteins containing MSP1 19 were expressed in bacteria with or without additional T-cell epitopes inserted between the GST and MSP1 19 . The epitopes selected were the universal TT-derived epitope P2 (44) and an I-A krestricted epitope (P8) from the P. falciparum antigen Pf332 (3). The proteins were used for immunization of four H-2 congenic mouse strains, of haplotypes H-2 b , H-2 d , H-2 k , and
. Immune responses after vaccination and protection against parasite challenge were assessed. The results demonstrate that insertion of T-cell epitopes into MSP1 19 based immunogens can enhance the immunoglobulin G (IgG) responses to MSP1 19 and can improve the protection against malaria parasite challenge. Additionally, it is shown that the P2 epitope, but not the P8 epitope, modulates the IgG subclass response to MSP1 19 . 19 . A plasmid encoding GST-MSP1 19 (36) , residues 1649 to 1754, of P. yoelii YM MSP1 (35) was modified to encode proteins with T-cell epitopes inserted between GST and MSP1 19 . A BamHI site in the plasmid, between the GST and the MSP1 19 genes, was digested with BamHI (Promega, Madison, Wis.), and the plasmid was dephosphorylated using alkaline phosphatase (Boehringer GmbH, Mannheim, Germany). Complementary oligonucleotides (VH BIO, Newcastle, United Kingdom) encoding the epitope P2 (IQYIKANSKFIGITEL) or P8 (EE-GPVDEEIVQEEGTV) were annealed by heating to 95°C followed by slow cooling to 20°C. The duplex oligonucleotide was phosphorylated using T4 polynucleotide kinase (Promega) and ligated into the BamHI site of the plasmid using T4 DNA ligase (Promega). Ligation reactions with a fivefold molar excess of oligonucleotide were used to transform Escherichia coli strain DH5␣. The oligonucleotides used were 5Ј-GAT CCA GTA CAT CAA AGC TAA CTC  CAA ATT CAT CGG TAT CAC CGA ACT GGG TCA GGT-3Ј (P2 sense),  5Ј-GAT CAC CTG ACC CAG TTC GGT GAT ACC GAT GAA TTT GGA  GTT AGC TTT GAT GTA CTG-3Ј (P2 antisense), 5Ј-GAT CCT GGA AGA  AGG TCC GGT TGA CGA AGA AAT CGT TCA GGA AGA AGG TAC  CGT-3Ј (P8 sense) , and 5Ј-GAT CAC GGT ACC TTC TTC CTG AAC GAT TTC TTC GTC AAC CGG ACC TTC TTC CAG-3Ј (P8 antisense) (nucleotides in boldface ensured re-creation of the BamHI site in the 5Ј ends of correct inserts and in the 3Ј ends of reversed inserts; underlined nucleotides encode a stop codon in reversed inserts). To identify plasmids with inserts, proteins expressed by transformed bacterial clones were analyzed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) (11) . Plasmids with correct inserts resulted in the expression of proteins larger than GST-MSP1 19 , and those with reversed inserts resulted in the expression of GST only. The number of inserts was determined by BamHI and EcoRI (Promega) restriction of plasmids. The EcoRI site is located immediately after the MSP1 19 sequence, and excised DNA fragments with correct inserts included the MSP1 19 sequence plus 50 to 60 bp for each insert, unlike the DNA fragments from plasmids with reversed inserts or the parental plasmid. Plasmids encoding GST-P2-MSP1 19 including two copies of P2 and GST-P8-MSP1 19 including one copy of P8 were identified, and the inserts were confirmed by DNA sequencing.
MATERIALS AND METHODS

Construction of plasmids encoding variants of recombinant GST-MSP1
Production, purification, and analysis of recombinant proteins. Recombinant proteins were produced as previously described, with modifications (36, 54) . Briefly, protein expression in transformed E. coli DH5␣ cells was induced with 1 mM isopropylthio-␤-galactosidase (Sigma) for 3 h at 37°C. The cells were harvested and lysed in phosphate-buffered saline (PBS). After centrifugation, the supernatant was incubated with glutathione-agarose (Sigma). Fusion proteins were eluted with 10 mM reduced glutathione (Sigma) and dialyzed against PBS. Solubilization of GST-P2-MSP1 19 required sonication of bacteria in 2 M urea. The corresponding supernatant was diluted to 0.5 M urea in PBS to enable binding to glutathione-agarose beads. The beads were washed with decreasing concentrations of urea in PBS and eventually with pure PBS before elution and dialysis as described above. To obtain GST-free MSP1 19 , GST-MSP1 19 was bound to glutathione-agarose and treated for 12 h at 22°C with factor Xa (Sigma), which cleaves a site right after the C terminus of GST. Factor Xa was removed by incubation with p-aminobenzamidine-agarose (Sigma). Simultaneous incubation with glutathione-agarose ensured that any contaminating GST was removed before dialysis against PBS. Protein concentrations were determined by multiplying the absorbance at 280 nm with a factor calculated for each protein according to protein size and content of aromatic amino acids (26) . The GST-MSP1 19 variants were further analyzed by Western blotting (11) , and GSTfree MSP1 19 was subjected to a dot blot assay (2) using the MSP1 19 -specific MAb B10 and F5 (55) .
MAPs. Multiple-antigen peptide (MAP) constructs (56) were made as control immunogens as well as for measurement of specific antibodies. Synthesis and analysis of MAP constructs were performed as described previously (1) . The MAP constructs had four identical peptide chains synthesized in parallel on the tetrameric lysine core. Amino acid analysis confirmed the right amino acid composition of each MAP. The sequences of MAP-P2 and MAP-P8 corresponded to those of the P2 and P8 epitopes in the recombinant proteins, respectively. P. yoelii parasites. Lethal P. yoelii YM parasites (63) were kindly provided by D. Walliker, Edinburgh University, and were kept in liquid nitrogen and by passage in mice. All infected mice were given drinking water supplemented with 2.5 g of p-aminobenzoic acid/liter (47) .
Immunization and parasite challenge of mice. Female B10.A(4R), B10.BR, C57BL/6, and B10.D2 mice (Harlan, Oxford, United Kingdom) ( Table 1) were used at 7 to 10 weeks of age. Groups of five mice were injected intraperitoneally (i.p.) with 40 g of GST-MSP1 19 , GST-P2-MSP1 19 , or a mixture of GST and MAP-P2 emulsified in complete Freund's adjuvant (Sigma). B10.A(4R), B10.BR, and C57BL/6 mice were also immunized with GST-P8-MSP1 19 , GST, or MAP-P8. Booster injections with 40 g of immunogen in incomplete Freund's adjuvant (Sigma) were given at weeks 3 and 6, and blood to obtain serum was drawn from the tail at week 8. One week later, mice were inoculated intravenously with 10 4 P. yoelii-infected RBC. Giemsa-stained blood smears were made daily from day 3 of the infection. Parasitemia was assessed by counting the percentage of infected RBC using light microscopy. Two additional groups of B10.A(4R) mice were immunized subcutaneously (s.c.) in the base of the tail with either GST-MSP1 19 or GST-free MSP1 19 . Otherwise, the immunizations were made as described above.
Assessment of antibody responses. For the enzyme-linked immunosorbent assay (ELISA), GST-free MSP1 19 , GST, or MAP constructs were adsorbed at 2 g/ml in PBS to Immulon 4 plates (Dynatech Laboratories, Inc., Billingshurst, United Kingdom) overnight at 8°C. The wells were blocked with 1% bovine serum albumin in PBS for 1 h at room temperature, and then duplicates of serum diluted in PBS with 0.1% bovine serum albumin and 0.05% Tween were added, and the wells were incubated for 1 h at 37°C. Between incubations, wells were washed with PBS containing 0.05% Tween. Specific antibodies were detected by incubation with rabbit anti-mouse IgG (Sigma), goat anti-mouse IgG1, IgG2b, or IgG3 (Southern Biotechnology, Birmingham, Ala.), or sheep anti-mouse IgG2a (The Binding Site, Birmingham, United Kingdom) conjugated to horseradish peroxidase. Absorbance was measured at 492 nm after adding o-phenylenediamine (Sigma) as the chromogen and H 2 O 2 as the substrate and later 1 M sulfuric acid to stop the reaction. Analyses were standardized by including a pool of mouse antisera to GST-MSP1 19 in all assays.
For indirect immunofluorescence antibody assay (IFAT), blood was drawn from P. yoelii YM-infected mice into heparinized tubes. The blood was washed and diluted 1:200 in phosphate-saline buffer with 0.2% glucose. Ten microliters of cell suspension was added to wells of 15-well multitest slides (ICN Biomedi- 
a Classes (I to III) are in parentheses. (b), the class II molecule I-E b is not expressed. b Individual sera from five mice per group immunized i.p. were titrated for reactivity with MSP1 19 . The reciprocal titers were estimated as the dilution corresponding to an absorbance value of 0.6. Mean reactivities of serum plus two standard deviations from all groups of mice immunized with GST/MAP-P2 were below 0.3 at dilutions of 1:1,000.
c nd, not done.
cals, Inc., Aurora, Ohio) that were air dried before storage at Ϫ20°C. Prior to the staining, the slides were fixed with acetone for 2 min and blocked in PBS with 1% bovine serum albumin for 30 min at room temperature. The wells were incubated for 1 h at 37°C with serum in consecutive twofold dilutions in PBS. Specific antibodies were detected by incubation for 1 h at 37°C with fluorescein isothiocyanate-conjugated goat anti-mouse IgG1, IgG2a, IgG2b, or IgG3 (Southern Biotechnology). Between incubations the slides were washed in PBS. Titers were determined as the reciprocal of the last positive dilution when analyzed by UV microscopy. Competition ELISA. Wells were adsorbed with MSP1 19 or 1 g of native MSP1/ml from P. yoelii YM as described above. Native MSP1 was purified as previously described (29) . The wells were blocked and incubated with duplicates of serum dilutions, followed by incubation with biotinylated MAb at concentrations established by titration. MAb B10, F5, and D3 (55) were biotinylated by mixing the MAb in PBS with sulfosuccimidyl-6-(biotinamido)-hexanoate (Pierce, Rockford, Ill.) for 1 h at room temperature, followed by dialysis against PBS. Bound MAb was detected by incubation with 1 g of avidin-peroxidase (Sigma)/ ml and addition of the substrate as described above. The level of competition was estimated by comparison with wells incubated with biotinylated MAb only.
Statistical analyses. Statistical analyses were made by linear regression or Student's t test (two-tailed, unpaired).
RESULTS
Production and analyses of recombinant proteins. Recombinant GST-MSP1 19 with or without T-cell epitopes inserted between GST and MSP1 19 were made. GST-P2-MSP1 19 included two copies of the universal epitope P2, and GST-P8-MSP1 19 included one copy of the I-A k -restricted epitope P8. According to SDS-PAGE, GST-MSP1 19 and variants thereof were predominantly full-length proteins and MSP1 19 , from which GST had been removed, was free from contamination. Proteins including P2 or P8 displayed increased relative molecular masses compared to GST-MSP1 19 (42 kDa) . Insertion of one P8 epitope resulted in an increase of 5 kDa, which is larger than expected (theoretically 1.5 kDa), most likely because of the highly negative charge of P8 (3). Insertion of two copies of P2 led to an expected increase of 3 kDa. MAb B10 and F5, which recognize parasite-derived MSP1 19 (55) , bound all GST-MSP1 19 variants in Western blotting, provided the SDS-PAGE separation was performed under nonreducing conditions. MAb B10 and F5 also recognized GST-free MSP1 19 in a dot blot assay.
P. yoelii challenge in mice immunized with GST-MSP1 19 variants. B10.A(4R) and B10.BR mice immunized with GST/ MAP-P2, GST-MSP1 19 , GST-P2-MSP1 19 , and GST-P8-MSP1 19 were challenged with 10 4 P. yoelii YM-infected RBC (Fig. 1 ). Naive control mice and the mice immunized with GST/ MAP-P2 rapidly developed high parasitemias and succumbed to the infection at days 7 to 9. Similarly, B10.A(4R) and B10.BR mice immunized with GST or MAP-P8 were not protected (data not shown). B10.A(4R) mice immunized with GST-MSP1 19 quickly developed high levels of parasites, but only one of the mice failed to clear the parasites and died at day 25. The protection of B10.BR mice immunized with GST-MSP1 19 was poor. Four mice died between days 8 and 10; one mouse survived but had a peak parasitemia of 42%. In B10.A (4R) mice, immunization with GST-P2-MSP1 19 resulted in good protection in three mice, which had parasitemias below 7%, but two mice developed high parasitemias and died at day 9. Immunization with GST-P8-MSP1 19 resulted in the survival of all five B10.A(4R) mice, with significantly lower peak parasitemias than were observed in the GST-MSP1 19 group (P ϭ 0.027). In B10.BR mice, GST-P2-MSP1 19 induced better protection than GST-MSP1 19 , in terms of increased survival as well as lower peak parasitemias (P ϭ 0.0074). Four out of five mice survived, and three of these had parasitemias below 5%. In B10.BR mice, GST-P8-MSP1 19 did not significantly improve protection although two mice survived and the death of one mouse was delayed (day 19).
Levels of protection induced by GST-MSP1 19 and GST-P2-MSP1 19 in C57BL/6 and B10.D2 mice were also compared (Fig. 1) . After immunization with GST-MSP1 19 , C57BL/6 mice were reasonably well protected, with peak parasitemias below 0.05% in three mice, although two mice slowly developed high parasitemias, which were cleared by day 23. B10.D2 mice were well protected, and only two mice had detectable parasitemias. There was no significant change in C57BL/6 and B10.D2 mice immunized with GST-P2-MSP1 19 . Immunization of C57BL/6 mice with GST-P8-MSP1 19 19 -specific IgG levels than B10.BR mice (P ϭ 0.0061 and 0.0052, respectively) and B10.A(4R) mice (P ϭ 0.032 and 0.032, respectively). The IgG titers in B10.A(4R) and B10.BR mice were increased twoto threefold after immunization with GST-P2-MSP1 19 compared to titers for mice immunized with GST-MSP1 19 (P ϭ 0.006 and 0.001, respectively), whereas in C57BL/6 and B10.D2 mice, IgG titers were no different or lower in GST-P2-MSP1 19 antisera. B10.A(4R) and B10.BR antisera to GST-P8-MSP1 19 displayed only slightly elevated MSP1 19 -specific IgG levels compared to sera from GST-MSP1 19 -immunized mice.
In all mice taken together, there was a significant inverse correlation of peak parasitemias and IgG titers to MSP1 19 (r ϭ 0.53; n ϭ 50; P Յ 0.0001).
IgG subclass responses in mice immunized with MSP1 19 -containing immunogens. The IgG subclass distribution of antibodies to MSP1 19 in prechallenge antisera from mice immunized with GST-MSP1 19 was examined by ELISA and was found to differ between mouse strains although, in all mice, IgG1 was detected at higher dilutions than other subtypes (IgG2b Ͼ IgG2a Ͼ IgG3) (Fig. 2) . In Fig. 2 ). C57BL/6 and B10.D2 mice displayed significantly higher IgG1 reactivity than both B10.A(4R) (P ϭ 0.015 and 0.0007, respectively) and B10.BR mice (P ϭ 0.0038 and 0.0005, respectively). B10.D2 mice also had significantly higher levels of IgG2a than B10.A(4R) (P ϭ 0.028) and B10.BR mice (P ϭ 0.0009). No significant differences between IgG2b and IgG3 levels were observed.
In mice immunized with GST-MSP1 19 , there was an inverse correlation between peak parasitemia and the levels of IgG1 (r ϭ 0.73; n ϭ 20; P ϭ 0.0003) and IgG2a (r ϭ 0.50; n ϭ 20; P ϭ 0.026), but not levels of IgG2b or IgG3.
In mice vaccinated with GST-P2-MSP1 19 , the IgG2a and IgG2b levels were elevated compared to levels in mice immunized with GST-MSP1 19 (Fig. 2) . The increases of both IgG2a and IgG2b levels in B10.BR mice were significant (P ϭ 0.0008 and P Յ 0.0001, respectively), as was the increase of IgG2a in B10.D2 (P ϭ 0.013) mice and the increases of IgG2b in B10.A(4R) (P ϭ 0.0003) and C57BL/6 (P ϭ 0.0073) mice. IgG1 levels were slightly increased in B10.(4R) and B10.BR mice and significantly decreased in C57BL/6 (P ϭ 0.027) and B10.D2 mice (P ϭ 0.0039). IgG3 was enhanced in all mice except B10.A(4R) mice after immunization with GST-P2-MSP1 19 , but only significantly so in B10.BR mice (P ϭ 0.0003). No significant change of any IgG subclass was observed in antisera to GST-P8-MSP1 19 (Fig. 4 ). An analysis of all groups of mice together found a significant association between low maximal parasitemia and high IgG1 (r ϭ 0.43; n ϭ 50; P ϭ 0.0019) or IgG2a levels (r ϭ 0.49; n ϭ 50; P ϭ 0.0003), but not IgG2b or IgG3 levels. Importantly, the levels of IgG1, IgG2a, and IgG2b detected by IFAT correlated with the reactivities of the corresponding IgG subclasses in the ELISA, confirming that the IgG levels determined by ELISA reflected reactivity with parasite-derived MSP1 19 (Table 2) .
In order to determine if the insertion of P2 into GST-MSP1 19 also affected the IgG subclass response to the GST fusion partner, B10.BR antisera to GST fusion proteins were analyzed by ELISA (Fig. 3) . The levels of IgG reactivity with GST in antisera to GST-MSP1 19 were lower than the levels of MSP1 19 -reactive IgG but displayed a similar IgG subclass distribution. Interestingly, antiserum to GST-P2-MSP1 19 had increased levels of IgG2a and IgG2b also to GST, in comparison with antisera to GST-MSP1 19 , GST-P8-MSP1 19 P2, suggesting that P2 influenced the IgG subclass response to GST as well as MSP1 19 . Moreover, B10.A(4R) antisera to GST-MSP1 19 and GSTfree MSP1 19 were compared for reactivity with MSP1 19 (Fig.  4) . Notably, these two groups of mice were immunized by s.c. injections, which resulted in slightly higher IgG responses to MSP1 19 
than those in mice immunized i.p. (data not shown).
Irrespective of that finding, the levels of IgG subclasses in the two groups immunized s.c. with GST-MSP1 19 and MSP1 19 were similar, indicating that the presence of GST did not influence the IgG subclass response to MSP1 19 (Fig. 4) .
Analysis of the epitope specificity induced by the GST-MSP1 19 variants. A competitive ELISA was used to analyze whether antisera from the different immunization groups differed not only in levels of MSP1 19 -specific IgG but also in their specificities for known, protective epitopes. Sera from mice immunized with GST-MSP1 19 variants were tested for the capacity to inhibit the binding of MAb F5 and B10 to MSP1 19 or MAb D3 to purified native MSP1 protein. All three MAb confer partial protection when passively transferred to mice (55) . MAb F5 recognizes an epitope in the first domain of MSP1 19 ; B10 requires both domains together for binding, and D3 binds P. yoelii MSP1 42 but not MSP1 19 or MSP1 33 separately (55) . All sera inhibited, to a variable extent, the binding of MAb F5 or B10 to MSP1 19 (Fig. 5) , whereas no inhibition of MAb D3 binding to MSP1 was observed. The inhibition of both MAb F5 and B10 was strongly associated with the levels of MSP1 19 -reactive IgG in the sera (Fig. 5) . Thus, although sera from well-protected mice displayed higher competition, the results do not suggest that the competitive capacity varied between groups due to major differences in epitope specificity. Competition with both MAb B10 and F5 was also inversely associated with peak parasitemia in the corresponding mice (r ϭ 0.49, n ϭ 50, P Յ 0.0001, and r ϭ 0.58, n ϭ 50, P Յ 0.0001, respectively).
DISCUSSION
Numerous studies have indicated the protective potential of the malaria antigen MSP1 19 . The levels of antibodies in malaria-exposed humans to P. falciparum MSP1 19 , or epitopes within MSP1 19 , are associated with clinical immunity (20, 51, 52) . Moreover, immunization of monkeys with antigens that include either P. falciparum or Plasmodium cynomolgi MSP1 19 confers protection (12, 34, 46) , although protection has not always been achieved or has been insufficient (10, 12, 34) . Similarly, inbred mouse strains can be protected against P. yoelii by immunization with GST linked to P. yoelii MSP1 19 (16, 36) but are differently protected in an H-2-dependent manner; C57BL/10 (H-2 b ) mice are better protected than B10.A(4R) (H-2 k/b ) and B10.BR (H-2 k ) mice (59) . The genetically restricted protection induced by GST-MSP1 19 was previously assessed using residues 1619 to 1754 of P. yoelii MSP1 (59). We found that using a shorter fragment of MSP1 (residues 1649 to 1754), still including both domains of MSP1 19 that are essential for induction of protection (37), did not change the relative protection observed in C57BL/6 (H-2 b ), B10.A(4R), and B10.BR mice. We also found that B10.D2 (H-2 d ) mice were similarly or slightly better protected than H-2 b mice. As a strategy to improve the protection induced by P. yoelii MSP1 19 , we inserted additional T-cell epitopes into GST-MSP1 19 and compared the protective capacities of these immunogens with GST-MSP1 19 . Insertion of the TT-derived Tcell epitope P2 in GST-MSP1 19 led to increased survival and protection against P. yoelii challenge infection in B10.BR mice, a mouse strain otherwise not protected by immunization with GST-MSP1 19 . Inclusion of the I-A k -restricted epitope P8 markedly improved the ability of B10.A(4R) mice to suppress parasitemia but had a lesser effect on B10.BR mice, suggesting that differences at the I-E locus or a minor histocompatibility locus may affect presentation of the P8 epitope. In mice well protected by GST-MSP1 19 (C57BL/6 and B10.D2 mice), insertion of P2 in the immunogen had no significant effect on protection. The course of infection in mice immunized with MAP constructs containing P2 or P8 was similar to that in GST-immunized or naive mice, demonstrating that immune responses to these epitopes were not protective.
The P2 epitope has been described as a universal T-cell epitope, and T cells from most TT-vaccinated humans recognize it (44) . When tested with B10.A(4R), B10.BR, C57BL/6, and DBA/2 (H-2 d ) mice, incorporation of P2 in a peptide immunogen enhanced the total IgG responses to otherwise poorly immunogenic B-cell epitopes in all mouse strains (33) . We have shown here that insertion of P2 into GST-MSP1 19 led to enhanced total IgG responses to MSP1 19 in B10.A(4R) and B10.BR mice but not in C57BL/6 and B10.D2 mice. However, in all mouse strains, GST-P2-MSP1 19 induced significantly increased levels of MSP1 19 -reactive IgG2a and/or IgG2b. The ability to modulate the IgG subclass response may be a general feature of P2, as IgG2a and IgG2b responses to the GST moiety were also enhanced. In contrast, P8 did not significantly change the IgG subclass pattern induced.
In mice, IgG1 responses are usually associated with Th2 responses whereas high levels of IgG2a, sometimes associated with IgG2b and IgG3, are thought to reflect Th1 responses (18, 22, 25, 27, 42) . Several parameters influence the IgG subclass responses to proteins, including the use of adjuvants or delivery systems as well as the intrinsic immunogenicity of the protein itself (13, 31, 53, 64) . The response elicited by GST-MSP1 19 , with high levels of multiple IgG subclasses, is thus likely to be a combined effect of several parameters. Nevertheless, Freund's adjuvant appears to be a strong regulator of immune responses and usually induces high IgG1 as well as considerable IgG2a and IgG2b levels, reflecting an adjuvantdependent mixed Th1/Th2 response (13, 15, 31, 62) . The modulation of IgG subclass responses induced by P2 suggests that T-cell responses to P2 can, to some extent, override other factors determining the IgG subclass response, possibly reflecting a polarization towards Th1, although studies on P2-induced cytokine responses are required to confirm this. The decreased IgG1 levels in H-2 b and H-2 d mice support this, but, in contrast, the IgG1 levels were slightly increased in H-2 k and H-2
mice. The decrease of IgG1 in H-2 b and H-2 d mice may explain why no improvement of the protection was observed in these mice following immunization with GST-P2-MSP1 19 . Moreover, the differential effect of P2 on the IgG response in mice with disparate H-2 haplotypes suggests that this epitope, despite being universally recognized, has a different impact on the IgG subclass response in a major histocompatibility complex-dependent manner.
The prechallenge levels of IgG to MSP1 19 , as well as the levels of specific IgG1 and IgG2a, in mice immunized with GST-MSP1 19 variants were inversely correlated with peak parasitemia. This is in agreement with previous studies that have implicated antibodies to P. yoelii MSP1 19 as the main effector mechanism for protection (14, 28, 36) . Specific IgG1 and IgG2a were found at higher levels in C57BL/6 and B10.D2 mice than in B10.BR or B10.A(4R) mice after immunization with GST-MSP1 19 , providing a plausible explanation for the differential protection in these mouse strains. Moreover, the enhanced levels of these IgG subclasses may be responsible for the improved protection of B10.BR mice immunized with GST-P2-MSP1 19 . Surprisingly, in the B10.A(4R) mice vaccinated with GST-P2-MSP1 19 , a similar improvement of the protection was not observed despite increased IgG levels. However, three mice in this group had peak parasitemias comparable to that of the most protected B10.A(4R) mouse in the GST-MSP1 19 group. Several pieces of evidence indicate an important role for IgG2a in protection against P. yoelii. Only the IgG2a fraction of isotype-and subclass-fractionated polyclonal antibodies to whole P. yoelii blood stage parasites was protective (60) . Also, mice inoculated with recombinant Mycobacterium bovis BCG bacteria expressing MSP1 19 were partially protected against P. yoelii; this was accompanied by rapid production of MSP1 19 specific IgG2a (but not IgG1, IgG2b, or IgG3) during challenge infection (41) . In contrast, in a study by Tian et al. (59) , protection following immunization with recombinant GST-MSP1 19 was associated with high levels of MSP1 19 -specific IgG1 and Hirunpetcharat et al. (28) found associations with IgG1 and IgG2b. The association between levels of both IgG1 and IgG2a to MSP1 19 and low peak parasitemia found in this study suggests that both of these IgG subclasses mediate protection against P. yoelii. Differences in immunization protocols and use of different mouse strains may to some extent underlie the different associations observed in these studies, but the choice of detection reagents can also affect measurement of IgG subclasses, especially IgG2a (40) .
The protective capacity of the IgG subclasses could relate to their differential recognition by Fc␥ receptors and thus their ability to trigger cell-mediated parasite clearance (19, 24, 49) . However, a recent study showed that Fc␥-receptor ␥-chain knockout mice were protected by passive transfer of antiserum to MSP1 19 (50) . Since IgG1, IgG2a, and IgG2b cannot mediate antibody-dependent cell-mediated cytotoxicity or phagocytosis in such mice and since antisera with low levels of IgG3 were used, the observed protection suggests that IgG specific for MSP1 19 can exert a direct inhibitory effect on the parasite (50). However, it does not follow that the subclass of the IgG response to MSP1 19 is irrelevant to its protective capacity. IgG Fc regions vary in size, shape, and mobility and can thus affect the ability of Fab regions to gain access to, and bind to, their binding site. Also, complement-mediated mechanisms relying on specific IgG subclasses may also contribute to protective immunity.
In mice immunized with GST-P8-MSP1 19 , protection was improved despite a relatively small increase of IgG levels compared to those in mice immunized with GST-MSP1 19 . Similarly, improved protection was also observed in B10.A(4R) mice immunized with GST-free P8-MSP1 19 despite a modest increase of IgG levels in comparison with those in MSP1 19 immunized mice (data not shown). Although even a slight increase in IgG is likely to have a positive effect on protection, other explanations could be sought as well. For example, antibodies with different fine specificities for P. falciparum MSP1 19 exert variable effects on the processing of MSP1 42 . Some antibodies inhibit the proteolytic processing, whereas others do not and may even block the effect of the inhibitory antibodies (9, 45). Whether or not IgG antibodies with such distinct activities are induced by P. yoelii MSP1 19 is not known. To examine if the groups of mice in the present study displayed different epitope specificities, antisera were analyzed for the capacity to inhibit the binding of MAb to P. yoelii MSP1 19 . Antisera from well-protected mice generally displayed better inhibition, but the inhibition appeared to be related to the total level of MSP1 19 -reactive IgG rather than reflecting drastically different epitope specificities between groups. A recent study indicated that the avidity of IgG elicited by GST-MSP1 19 is of importance for protection against P. yoelii. Prechallenge sera from protected mice vaccinated with GST-MSP1 19 protein not only had higher levels of multiple IgG subclasses but also displayed a higher avidity for MSP1 19 than sera from nonprotected mice immunized by DNA vaccination (32) . It was also observed that B10.BR mice immunized with GST-MSP1 19 in Freund's adjuvant responded with lower avidity than C57BL/ 10 mice (32). Thus, since high-avidity responses depend on somatic mutation in B cells, which is a T-cell-dependent process, inclusion of additional T-cell epitopes in GST-MSP1 19 may improve the protection by enhancing IgG avidity as well as antibody titers.
In summary, the genetically restricted protection against P. yoelii induced by GST-MSP1 19 in mice can be overcome by inserting additional T-cell epitopes into the immunogen. Importantly, both T-cell epitopes used in the present study could enhance the IgG responses to MSP1 19 but one of them (P2) also modulated the IgG subclass response. The enhanced IgG responses induced by the modified GST-MSP1 19 variants are likely to explain the improved protection, as the prechallenge levels of both IgG1 and IgG2 were inversely correlated with peak parasitemia after infection. Whether or not inclusion of additional T-cell epitopes in a P. falciparum MSP1 19 vaccine will overcome problems of low immunogenicity and poor Tcell activation associated with immune responses to P. falciparum MSP1 19 in humans (21) remains to be investigated.
